Drug: Topical Rapamycin
Phase 2Small molecule
Drug: Topical Rapamycin is one of 6 small molecule programs targeting Sturge-Weber syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Sturge-Weber Syndrome
#DrugCompanyPhaseTrials
1Afinitor
NovartisPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Epidiolex
Jazz PharmaceuticalsPhase 1
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
QLS-101
QQlaris Bio, Inc.
Phase 2
Drug: Topical Rapamycin
CClinica Universidad de Navarra, Universidad de Navarra
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sturge-Weber syndrome1 trial
Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome
Completed·—·Phase 2·NCT02080624·23 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Drug: Topical Rapamycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details